Virus entry: Molecular mechanisms and biomedical applications

Nature Reviews Microbiology

Volumn 2, Issue 2, 2004, Pages 109-122

  Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; ANTIVIRUS AGENT; CD4 ANTIGEN; CELL SURFACE RECEPTOR; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; DOUBLE STRANDED DNA; ENFUVIRTIDE; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN ANTIBODY; LIPOSOME; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 447 52D; MONOCLONAL ANTIBODY 4E; MONOCLONAL ANTIBODY B12; MONOCLONAL ANTIBODY X5; MONOCLONAL ANTIBODY Z13; NEUTRALIZING ANTIBODY; PALIVIZUMAB; PLECONARIL; PROTEIN F; PROTEIN L; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIROSOME; VIRUS ENVELOPE PROTEIN; VIRUS FUSION PROTEIN; VIRUS PROTEIN; VIRUS RECEPTOR; VIRUS RNA; VIRUS ANTIBODY; VIRUS VACCINE;

ANTIVIRAL ACTIVITY; BINDING AFFINITY; CONFORMATIONAL TRANSITION; DNA VIRUS; DRUG APPROVAL; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TARGETING; ENDOCYTOSIS; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID VESICLE; MEDICAL RESEARCH; MEMBRANE FUSION; MOLECULAR BIOLOGY; MOLECULAR RECOGNITION; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN INTERACTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RNA VIRUS; RNA VIRUS INFECTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENETICS; VIRUS ADSORPTION; VIRUS CELL INTERACTION; VIRUS CLASSIFICATION; VIRUS ENVELOPE; VIRUS GENOME; VIRUS INHIBITION; VIRUS MORPHOLOGY; VIRUS PATHOGENESIS; VIRUS VIRULENCE; ANIMAL; CHEMISTRY; IMMUNOLOGY; PATHOGENICITY; PHYSIOLOGY; PROTEIN CONFORMATION; ULTRASTRUCTURE; VIRUS;

ADENOVIRIDAE; ANIMALIA; ARCHAEA; COXSACKIEVIRUS; DNA VIRUSES; EUKARYOTA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS; RNA VIRUSES;

ANIMALS; ANTIBODIES, VIRAL; HUMANS; MEMBRANE FUSION; PROTEIN CONFORMATION; RECEPTORS, VIRUS; VIRAL VACCINES; VIRUSES;

EID: 1842612607     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro817     Document Type: Review

References (112)

1. d'Herelle, F. The Bacteriophage and its Behavior (Williams and Wilkins, Baltimore, USA, 1926).
2. Sieczkarski, S. B. & Whittaker, G. R. Dissecting virus entry via endocytosis. J. Gen. Virol. 83, 1535-1545 (2002).
3. Pelkmans, L., Puntener, D. & Helenius, A. Local actin polymerization and dynamin recruitment in SV40-induced internalization of caveolae. Science 296, 535-539 (2002).
4. Dimitrov, D. S. Cell biology of virus entry. Cell 101, 697-702 (2000).
5. Rawat, S. S. et al. Modulation of entry of enveloped viruses by cholesterol and sphingolipids. Mol. Membr. Biol. 20 243-254 (2003).
6. Takeda, M., Leser, G. P., Russell, C. J. & Lamb, R. A. Influenza virus hemagglutinin concentrates in lipid raft microdomains for efficient viral fusion. Proc. Natl Acad. Sci. USA 100, 14610-14617 (2003).
7. Waarts, B. L., Bittman, R. & Wilschut, J. Sphingolipid and cholesterol dependence of α-virus membrane fusion. Lack of correlation mith lipid raft formation in target liposomes. J. Biol. Chem. 277, 38141-38147 (2002).
8. Kielian, M., Chatterjee, P. K., Gibbons, D. L. & Lu, Y. E. Specific roles for lipids in virus fusion and exit. Examples from the α-viruses. Subcell. Biochem. 34, 409-455 (2000).
9. Igakura, T. et al. Spread of HTLV-I betmeen lymphocytes by virus-induced polarization of the cytoskeleton. Science 299 1713-1716 (2003).
10. Bomsel, M. & Alfsen, A. Entry of viruses through the epithelial barrier: pathogenic trickery. Nature Rev. Mol. Cell Biol. 4, 67-68 (2003).
11. Seisenberger, G. et al. Real-time single-molecule imaging of the infection pathway of an adeno-associated virus. Science 294, 1929-1932 (2001).
12. Lowy, R. J., Sarkar, D. P., Chen, Y. & Blumenthal, R. Observaton of single influenza virus-cell fusion and measurement by fluorescence video microscopy. Proc. Natl Acad. Sci. USA 87, 1850-1854 (1990).
13. Lakadamyali, M., Rust, M. J., Babcock, H. P. & Zhuang, X. Visualizing infection of individual influenza viruses. Proc. Natl Acad. Sci. USA 100, 9280-9285 (2003).
14. + cells: implications for inhibition of virus infection and initial steps of virus entry into cells. Virology 187, 398-406 (1992).
15. Dimitrov, D. S. et al. Quantitation of HIV-1 infection kinetics. J. Virol. 67, 2182-2190 (1993).
16. White, J., Kartenbeck, J. & Helenius, A. Fusion of Semliki forest virus with the plasma membrane can be induced by low pH. J. Cell. Biol. 87, 264-272 (1980).
17. Carr, C. M., Chaudhry, C. & Kim, P.S. Infuenza hemagglutinin is spring-loaded by a metastable native conformation. Proc. Natl Acad. Sci. USA 94, 14306-14313 (1997).
18. Hogle, J. M. Poliovirus cell entry: common structural themes in viral cell entry pathways. Annu. Rev. Microbiol. 56, 677-702 (2002).
19. Stubbs, M. T. Anthrax X-rayed: new opportunities for biodefence. Trends Pharmacol. Sci. 23, 530-541 (2002).
20. Chen, Y. A. & Scheller, R. H. SNARE-mediated membrane fusion. Nature Rev. Mol. Cell Biol. 2, 98-106 (2001).
21. Rossmann, M. G. et al. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 317, 145-153 (1985).
22. Hogle, J. M., Chow, M. & Filman, D. J. Three-dimensional structure of poliovirus at 2.9 A resolution. Science 229, 1358-1365 (1985).
23. Mancini, E. J., Clarke, M., Gowen, B. E., Rutten, T. & Fuller, S. D. Cryo-electron microscopy reveals the functional organization of an enveloped virus, Semliki Forest virus. Mol. Cell 5, 258-266 (2000).
24. Kuhn, R. J. et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108, 717-725 (2002).
25. Chappell, J. D., Prota, A. E., Dermody, T. S. & Stehle, T. Crystal structure of reovirus attachment protein σ1 reveals evolutionary relationship to adenovirus fiber. EMBO J. 21, 1-11 (2002).
26. Wilson, I. A., Skehel, J. J. & Wiley, D. C. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution. Nature 289, 368-373 (1981).
27. Chen, L. et al. The structure of the fusion glycoprotein of Newcastle disease virus suggests a novel paradigm for the molecular mechanism of membrane fusion. Structure 9, 258-266 (2001).
28. Rey, F. A., Heinz, F. X., Mandl, C., Kunz, C. & Harrison, S. C. The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution. Nature 375, 291-298 (1995).
29. Modis, Y., Ogata, S., Clements, D. & Harrison, S. C. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl Acad. Sci. USA 100, 6986-6991 (2003).
30. Lescar, J. et al. The fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH. Cell 105, 137-148 (2001).
31. Heinz, F. X. & Allison, S. L. The machinery for flavivirus fusion with host cell membranes, Curr. Opin. Microbiol. 4, 450-455 (2001).
32. Colman, P. M. & Lawrence, M. C. The structural biology of type I viral membrane fusion. Nature Rev. Mol. Cell Biol. 4, 309-319 (2003).
33. Carfi, A. et al. Herpes simplex virus glycoprotein D bound to the human receptor HveA. Mol. Cell 8, 169-179 (2001).
34. Fuss, D. et al. Structure of a murine leukemia virus receptor-binding glycoprotein at 2.0 angstrom resolution. Science 277, 1662-1666 (1997).
35. Wimmer, E. (ed.) Cellular receptors for animal viruses. 1-13 (Cold Spring Harbor Laboratory Press, New York, 1994).
36. Baranowski, E., Ruiz-Jarabo, C. M. & Domingo, E. Evolution of cell recognition by viruses. Science 292, 1102-1105 (2001).
37. Wang, J. Protein recognition by cell surface receptors: physiological receptors versus virus interactions, Trends Biochem. Sci. 27, 122-126 (2002).
38. Skehel, J. J. & Wiley, D. C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69, 531-569 (2000).
39. Kwong, P. D. et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648-659 (1998).
40. Harouse, J. M. et al. Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide. Science 253, 320-323 (1991).
41. Fingeroth, J. D. et al. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc. Natl Acad. Sci. USA 81, 4510-4514 (1984).
42. Dalgleish, A. G. et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312, 763-767 (1984).
43. Klatzmann, D. et al. T-lymphocyte T4 molecule behaves as the receptor for human rat retrovirus LAV. Nature 312, 767-768 (1984).
44. Feng, Y., Broder, C. C., Kennedy, P. E. & Berger, E. A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272, 872-877 (1996).
45. Wang, X., Huong, S. M., Chiu, M. L., Raab-Traub, N. & Huang, E. S. Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature 424, 456-461 (2003).
46. Geraghty, R. J., Krummenacher, C., Cohen, G. H., Eisenberg, R. J. & Spear, P. G. Entry of α-herpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor Science 280 1616-1620 (1998).
47. Li, W. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450-454 (2003).
48. Xiao, X., Chakraborti, S., Dimitrov, A. S., Gramatikoff, K. & Dimitrov, D. S. The SARS-CoV S glycoprotein: expression and functional characterization. Biochem. Biophys. Res. Commun. 312, 1159-1164 (2003).
49. Hammache, D., Yahi, N., Maresca, M., Pieroni, G. & Fantini, J. Human erythrocyte glycosphingolipids as alternative cofactors for human immunodeficiency virus type 1 (HIV-1) entry: evidence for CD4-induced interactions between HIV-1 gp120 and reconstituted membrane microdomains of glycosphingolipids (Gb3 and GM3). J. Virol. 73 5244-5248 (1999).
50. Percherancier, Y. et al. HIV-1 entry into T-cells is not dependent on CD4 and CCR5 localization to sphingolipid-enriched, detergant-resistant, raft membrane domains. J. Biol. Chem. 278 3153-3161 (2003).
51. Remeta, D. P. et al. Acid-induced changes in thermal stability and fusion activity of influenza hemagglutinin. Biochemistry 41, 2044-2054 (2002).
52. Blumenthal, R., Clague, M. J., Durell, S. R. & Epand, R. M. Membrane fusion. Chem. Rev. 103, 53-69 (2003).
53. Barnard, R. J. & Young, J. A. α-retrovirus envelope-receptor interactions. Curr. Top. Microbiol. Immunol. 281, 107-136 (2003).
54. Mothes, W., Boerger, A. L., Narayan, S., Cunningham, J. M. & Young, J. A. Retroviral entry mediated by receptor priming and low pH triggering of an envelope glycoprotein. Cell 103, 679-689 (2000).
55. Earp, L. J., Delos, S. E., Netter, R. C., Bates, P. & White, J. M. The avian retrovir us avian sarcoma/leukosis virus subtype A reaches the lipid mixing stage of fusion at neutral pH. J. Virol. 77, 3058-3066 (2003).
56. Eckert, D. M. & Kim, P. S. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70, 777-810 (2001).
57. Bosch, B. J., van der Zee, R., de Haan, C. A. & Rottier, P. J. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J. Virol. 77, 8801-8811 (2003).
58. Leikina, E., Ramos, C., Markovic, I., Zimmerberg, J. & Chernomordik, L. V. Reversible stages of the low-pH-triggered conformational change in influenza virus hemagglutinin. EMBO J. 21, 5701-5710 (2002).
59. Gallo, S. A. et al. The HIV Env-mediated fusion reaction. Biochim. Biophys. Acta 1614, 36-50 (2003).
60. Madhusoodanan, M. & Lazaridis, T. Investigation of pathways for the low-pH conformational transition in influenza hemagglutinin. Biophys. J. 84, 1926-1939 (2003).
61. Stiasny, K., Koessl, C. & Heinz, F. X. Involvement of lipids in different steps of the flavivirus fusion mechanism. J. Virol. 77, 7856-7862 (2003).
62. 125I]iodonaphthyl azide photolabeling studies in biological membranes. Biochemistry 36, 8890-8896 (1997).
63. Gaudin, Y. Reversibility in fusion protein conformational changes. The intriguing case of rhabdovirus-induced membrane fusion. Subcell. Biochem. 34, 379-408 (2000).
64. Roche, S. & Gaudin, Y. Characterization of the equilibrium between the native and fusion-inactive conformation of rabies virus glycoprotein indicates that the fusion complex is made of several trimers, Virology 297, 128-135 (2002).
65. Clague, M. J., Schoch, C., Zech, L. & Blumenthal, R. Gating kinetics of pH-activated membrane fusion of vesicular stomatitis virus with cells: stopped-flow measurements by dequenching of octadecylrhodamine fluorescence. Biochemistry 29, 1303-1308 (1990).
66. Lee, J. & Lentz, B. R. Secretory and viral fusion may share mechanistic events with fusion between curved lipid bilayers. Proc. Natl Acad. Sci. USA 95, 9274-9279 (1998).
67. Markosyan, R. M., Cohen, F. S. & Melikyan, G. B. HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation, Mol, Biol. Cell 14, 926-938 (2003).
68. Carr, C. M. & Kim, P. S. A spring-loaded mechanism for the centormational changes of influenza hemagglutinin. Cell 73, 823-832 (1993).
69. Gruenke, J. A., Armstrong, R. T., Newcomb, W. W., Brown, J. C. & White, J. M. New insights into the spring-loaded conformational change of infuenza virus hemagglutinin. J. Virol. 76, 4456-4466 (2002).
70. Chernomordik, L. V., Leikina, E., Frolov, V., Bronk, P. & Zimmerberg, J. An early stage of membrane fusion mediated by the low pH conformation of influenza hemagglutinin depends upon membrane lipids. J. Cell Biol. 136, 81-93 (1997).
71. Melikyan, G. B. & Chernomordik, L. V. Membrane rearrangements in fusion mediated by viral proteins. Trends. Microbiol. 5, 349-355 (1997).
72. Chernomordik, L., Leikina, E., Cho, M. S. & Zimmerberg, J. Centre of baculovirus gp64-induced syncytium formation by membrane lipid composition (published erratum appears in J. Virol. 69, 5928). J. Virol. 69, 3049-3058 (1995).
73. Gaudin, Y., Tuffereau, C., Durrer, P., Flamand, A. & Ruigrok, H. W. Biological function of the low-pH, fusion-inactive conformation of rabies virus glycoprotein (G): G is transported in a fusion-inactive state-like conformation. J. Virol. 69, 5528-5534 (1995).
74. LaBonte, J. A., Madani, N. & Sodroski, J. Cytolysis by CCR5-using human immunodefiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by hign levels of CD4 expression. J. Virol. 77, 6645-6659 (2003).
75. Duelli, D. & Lazebnik, Y. Cell fusion: a hidden enemy? Cancer Cell 3, 445-448 (2003).
76. De Clercq, E. Nee anti-HIV agents and targets. Med. Res. Rev. 22, 531-565 (2002).
77. Pollack, P. & Groothuis, J. R. Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV. J. Infect. Chemother. 8, 201-206 (2002).
78. Kilby, J. M. & Eron, J. J. Novel therapies based on mecnanisms of HIV-1 cell entry. N. Engl. J. Med. 348, 2228-2238 (2003).
79. Sawyer, L. A. Antibodies for the prevention and treatment of viral diseases. Antiviral Res. 47, 57-77 (2000).
80. Florea, N. R., Maglio, D. & Nicolau, D. P. Pleconaril, a novel antipicornaviral agent. Pharmacother. 23, 339-348 (2003).
81. Wei, X. et al. Antibooy neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
82. Kwong, P. D. et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420, 678-682 (2002).
83. Root, M. J., Kay, M. S. & Kim, P. S. Protein design of an HIV-1 entry inhibitor. Science 291, 884-888 (2001).
84. Lin, P. F. et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl Acad. Sci. USA 100, 11013-11018 (2003).
85. Arkin, M. R. et al. Binding of small molecules to an adaptive protein-prefer interface. Proc. Natl Acad. Sci. USA 100 1603-1608 (2003).
86. Shuker, S. B., Hajduk, P. J., Meadows, R. P. & Fesik, S. W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274, 1531-1534 (1996).
87. Braisted, A. C. et al. Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. J. Am. Chem. Soc. 125, 3714-3715 (2003).
88. Dimmock, N.J. Neutralization of animal viruses. Curr. Top. Microbiol. Immunol. 183, 1-149 (1993).
89. Burton, D. R. Antibodies, viruses and vaccines. Nature Rev. Immunol. 2, 708-713 (2002).
90. Smith, T. J. Antibody interactions with rhinovirus: lessons for mechanisms of neutralization and the role of immunity in viral evolution. Curr. Top. Microbiol. Immunol. 260, 1-28 (2001).
91. Johnson, S. et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176, 1215-1224 (1997).
92. Johnson, S. et al. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZ19. J. Infect. Dis. 180, 35-40 (1999).
93. Smith, T. J., Chase, E. S., Schmidt, T. J., Olson, N. H. & Baker, T. S. Neutralzing antibody to human rhinovirus 14 penetrates the receptor-binding canyon. Nature 383, 359-354 (1996).
94. Choe, H. et al. Tyrosine sulfation of human antibodies contributes to recogntion of the CCR5 binding region of HIV-1 gp120. Cell 114, 161-170 (2003).
95. Colman, P. M. Virus versus antibody. Structure. 5 591-593 (1997).
96. Skehel, J. J. & Wiley, D. C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69, 531-569 (2000).
97. Moulard, M. et al. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc. Natl Acad. Sci. USA 99, 6913-6918 (2002).
98. Frendo, J. L. et al. Direct involvement of HERV-W Env glycoprotein in human trophoblast cell fusion and differentiation. Mol. Cell Biol. 23, 3568-3574 (2003).
99. Harris, J. R. Placental endogenous retrovirus (ERV): structural, functional, and evolutionary significance. Bioessays 20, 307-316 (1998).
100. Thomas, C. E., Ehrhardt, A. & Kay, M. A. Progress and problems with the use of viral vectors for gene therapy. Nature Rev. Genet. 4, 348-358 (2003).
101. Sarkar, D. P., Ramani, K. & Tyagi, S. K. Targeted gene delivery by virosomes. Methods Mol. Biol. 199, 163-173 (2002).
102. Yamada, T. et al. Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nature Biotechnol. 21, 885-890 (2003).
103. Soong, N. W. et al. Molecular breeding of viruses. Nature Genet. 25, 438-439 (2000).
104. Perabo, L. et al. In vitro selection of viral vectors with modified tropism: the adeno-associated virus display. Mol. Ther. 8, 151-157 (2003).
105. Xie, Q. et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl Acad. Sci. USA 99, 10405-10410 (2002).
106. Belnap, D.M. et al. Molecular tectonic model of virus structural transitions: the putative cell entry states of poliovirus. J. Virol. 74, 1342-1354 (2000).
107. Ksiazek, T. G. et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1953-1966 (2003).
108. Stehle, T. & Dermody, T. S. Structural evidence for common functions and ancestry of the reovirus and adenovirus attachment proteins. Rev. Med. Virol. 13, 123-132 (2003).
109. Weis, W. et al. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature 333, 426-431 (1988).
110. Morton, C. J. et al. Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assay. Virology 311, 276-288 (2003).
111. Bewley, M. C., Springer, K., Zhang, Y. B., Freimuth, P. & Flanagan, J. M. Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR. Science 286, 1579-1583 (1999).
112. Xing, L. et al. Distinct cellular receptor interactions in poliovirus and rhinoviruses. EMBO J. 19, 1207-1216 (2000).